Febuxostat ameliorates secondary progressive experimental autoimmune encephalomyelitis by restoring mitochondrial energy production in a GOT2-dependent manner
暂无分享,去创建一个
S. Sakoda | Y. Nakatsuji | Tsutomu Sasaki | M. Kinoshita | A. Kumanogoh | H. Mochizuki | T. Okuno | M. Sakaguchi | T. Koda | K. Takata | K. Yamashita | Mikito Shimizu | A. Namba | J. A. Honorat | H. Sumi‐Akamaru | Takashi Shirakura | Mizuho Tamura | Eri Sanda
[1] C. Hoogenraad,et al. Axonal transport deficits in multiple sclerosis: spiraling into the abyss , 2017, Acta Neuropathologica.
[2] D. Minchenko,et al. Effect of hypoxia on the expression of nuclear genes encoding mitochondrial proteins in U87 glioma cells. , 2016, Ukrainian biochemical journal.
[3] M. Ricciutelli,et al. Proteomic analysis for early neurodegenerative biomarker detection in an animal model. , 2016, Biochimie.
[4] Xianbao Wang,et al. Febuxostat pretreatment attenuates myocardial ischemia/reperfusion injury via mitochondrial apoptosis , 2015, Journal of Translational Medicine.
[5] Bo Eun Lee,et al. Inhibition of NADPH oxidase activation reduces EAE-induced white matter damage in mice , 2015, Journal of Neuroinflammation.
[6] A. Lo,et al. Treatment of progressive multiple sclerosis: what works, what does not, and what is needed , 2015, The Lancet Neurology.
[7] F. Paul,et al. Oxidative damage to mitochondria at the nodes of Ranvier precedes axon degeneration in ex vivo transected axons , 2014, Experimental Neurology.
[8] P. Arun,et al. Acute mitochondrial dysfunction after blast exposure: potential role of mitochondrial glutamate oxaloacetate transaminase. , 2013, Journal of neurotrauma.
[9] S. Sakoda,et al. Xanthine Oxidase Mediates Axonal and Myelin Loss in a Murine Model of Multiple Sclerosis , 2013, PloS one.
[10] H. Lassmann,et al. Oxidative damage in multiple sclerosis lesions , 2011, Brain : a journal of neurology.
[11] Jianyi(Jay) Zhang,et al. Effect of Acute Xanthine Oxidase Inhibition on Myocardial Energetics During Basal and Very High Cardiac Workstates , 2011, Journal of cardiovascular translational research.
[12] Mary T. Brinkoetter,et al. A reversible form of axon damage in experimental autoimmune encephalomyelitis and multiple sclerosis , 2011, Nature Medicine.
[13] Richard Reynolds,et al. Mitochondrial DNA deletions and neurodegeneration in multiple sclerosis , 2011, Annals of neurology.
[14] R. Reynolds,et al. A Gradient of neuronal loss and meningeal inflammation in multiple sclerosis , 2010, Annals of neurology.
[15] Daniela Prayer,et al. Reduced NAA-Levels in the NAWM of Patients with MS Is a Feature of Progression. A Study with Quantitative Magnetic Resonance Spectroscopy at 3 Tesla , 2010, PloS one.
[16] H. Weiner,et al. Toll-like receptor 2 and poly(ADP-ribose) polymerase 1 promote central nervous system neuroinflammation in progressive EAE , 2009, Nature Immunology.
[17] Peter K Stys,et al. Virtual hypoxia and chronic necrosis of demyelinated axons in multiple sclerosis , 2009, The Lancet Neurology.
[18] S. Sakoda,et al. Edaravone, a free radical scavenger, ameliorates experimental autoimmune encephalomyelitis , 2008, Neuroscience Letters.
[19] Bruce D. Trapp,et al. Pathogenesis of axonal and neuronal damage in multiple sclerosis , 2007, Neurology.
[20] F. Barkhof,et al. N-acetylaspartic acid in cerebrospinal fluid of multiple sclerosis patients determined by gas-chromatography-mass spectrometry , 2007, Journal of Neurology.
[21] J. Moffett,et al. N-Acetylaspartate in the CNS: From neurodiagnostics to neurobiology , 2007, Progress in Neurobiology.
[22] R. Rudick,et al. Mitochondrial dysfunction as a cause of axonal degeneration in multiple sclerosis patients , 2006, Annals of neurology.
[23] Matthijs Oudkerk,et al. 1H MR spectroscopy of the brain in multiple sclerosis subtypes with analysis of the metabolite concentrations in gray and white matter: initial findings , 2006, European Radiology.
[24] S. Wehrli,et al. Response of brain amino acid metabolism to ketosis , 2005, Neurochemistry International.
[25] B. Trapp,et al. Axonal loss in the pathology of MS: consequences for understanding the progressive phase of the disease , 2003, Journal of the Neurological Sciences.
[26] K. Jellinger,et al. Preferential Loss of Myelin‐Associated Glycoprotein Reflects Hypoxia‐Like White Matter Damage in Stroke and Inflammatory Brain Diseases , 2003, Journal of neuropathology and experimental neurology.
[27] Friedrich C. Luft,et al. Endothelial Dysfunction and Xanthine Oxidoreductase Activity in Rats With Human Renin and Angiotensinogen Genes , 2001, Hypertension.
[28] R. Rudick,et al. Neurological disability correlates with spinal cord axonal loss and reduced N‐acetyl aspartate in chronic multiple sclerosis patients , 2000, Annals of neurology.
[29] M. McKenna,et al. Differential distribution of the enzymes glutamate dehydrogenase and aspartate aminotransferase in cortical synaptic mitochondria contributes to metabolic compartmentation in cortical synaptic terminals , 2000, Neurochemistry International.
[30] M. Rivera-Gaxiola,et al. Effect of nmda antagonists on the activity ofglutaminase and aspartate aminotransferase in thedeveloping rat cerebellum , 1999, International Journal of Developmental Neuroscience.
[31] P. Hanson,et al. Explorer Mitochondrial changes within axons in multiple sclerosis , 2017 .
[32] Д. О. Цимбал,et al. EffEct of hypoxia on thE ExprEssion of nuclEar gEnEs Encoding mitochondrial protEins in u 87 glioma cElls , 2016 .
[33] Hans Lassmann,et al. Progressive multiple sclerosis: pathology and pathogenesis , 2012, Nature Reviews Neurology.
[34] D. Turnbull,et al. Mitochondrial dysfunction plays a key role in progressive axonal loss in Multiple Sclerosis. , 2005, Medical hypotheses.